Clinical trials in BioPharma
A recent study revealed that biotechnology companies or universities discovered 42 percent of all innovative drugs approved by the US Food and Drug Administration (FDA) between 1998 and 2007.
Clinical trials and stratified medicine—maximising patent exclusivity
The traditional business model for a new drug relies on a substantial period of market exclusivity to recoup extensive research and development costs.
Traditional medicine patents lead to enhanced drug discovery from natural products
Natural products have been used to relieve a variety of diseases and conditions for millennia.
US Patent Law changes appear imminent
US patent reform looks like it may finally be coming. John Pegram and Mark Ellinger explain the proposed changes.
Attacking the validity of selection patents
The Canadian Federal Court of Appeal recently considered whether ‘invalid selection’ can be an independent ground for invalidating selection patents. Katie Wang looks at the implications.
The Brazilian pharmaceutical sector: a year in review
Practitioners can take heart from recent developments in the Brazilian courts, say Otto Licks and Anderson Nascimento.
Patentability of dosage regimens in Europe
First instance courts in France have adopted controversial interpretations of an important Enlarged Board of Appeal decision, says Stéphane Agasse.
Recognising equivalence, reciprocity and respect
Homologation (recognition of equivalence) is a useful tool for simplifying administrative processes that are repeated in different countries. Nevertheless, it is not an end in itself.
Windows of opportunity and closing doors at the EPO
There is a general acceptance that European patent law is complicated, particularly in the area of pharmaceutical inventions. Claire Baldock looks at how the EPO approaches these inventions.
Product definition in Swedish SPCs
There is a contradiction at the heart of product definition in Swedish supplementary protection certificates, says Hampus Rystedt.